(Q47281487)

13 January 2018

review article

1 reference

title

Monitoring of low-molecular-weight heparins in cardiovascular disease (English)

1 reference

13 January 2018

main subject

cardiovascular disease

1 reference

2

1 reference

13 January 2018

author name string

R Abbate

1

1 reference

13 January 2018

A Farsi

3

1 reference

13 January 2018

M Attanasio

4

1 reference

13 January 2018

G Pepe

5

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 September 1998

1 reference

13 January 2018

American Journal of Cardiology

published in

1 reference

13 January 2018

volume

82

1 reference

13 January 2018

issue

5B

1 reference

13 January 2018

page(s)

33L-36L

1 reference

13 January 2018

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Low molecular weight heparin(s).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Regulation of coagulation by a multivalent Kunitz-type inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Low molecular weight heparins: a developmental perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900111-8

10.1016/S0002-9149(98)00111-8

7 January 2021

Identifiers

DOI

1 reference

13 January 2018

1 reference

13 January 2018